Quarterly ResultMay 5, 2026, 04:08 PM
Avanos Medical Q1 Net Sales $182.2M; Net Income $5.1M
AI Summary
Avanos Medical reported mixed financial results for the first quarter of 2026. Net sales increased to $182.2 million, up from $167.5 million in the prior year period. However, net income decreased to $5.1 million, resulting in diluted earnings per share of $0.11, down from $0.14. The company continued its restructuring initiatives and integrated the Nexus Medical acquisition, which contributed $5.8 million in net sales during the quarter.
Key Highlights
- Net sales increased to $182.2 million in Q1 2026 from $167.5 million in Q1 2025.
- Net income decreased to $5.1 million in Q1 2026 from $6.6 million in Q1 2025.
- Diluted EPS was $0.11 in Q1 2026, down from $0.14 in Q1 2025.
- Specialty Nutrition Systems (SNS) net sales were $124.0 million in Q1 2026.
- Pain Management and Recovery (PM&R) net sales were $56.3 million in Q1 2026.
- Cash and cash equivalents stood at $65.6 million as of March 31, 2026.
- Restructuring costs incurred were $1.8 million in Q1 2026, down from $3.1 million.
- Nexus Medical acquisition contributed $5.8 million in net sales for Q1 2026.